TITLE

Teva/Active Biotech: laquinimod clinical program moves on

PUB. DATE
July 2007
SOURCE
PharmaWatch: CNS;Jul2007, Vol. 6 Issue 7, p5
SOURCE TYPE
Market Research Report
DOC. TYPE
Editorial
ABSTRACT
The author reflects on the gap that exists in the orally administered treatments for relapsing multiple sclerosis (MS). He asserts that laquinomoid, an autoimmune suppressant used for treating relapsing MS, is behind from other oral MS treatments in the clinical trial process. He stresses that Teva Pharmaceutical Industries Ltd. and Active Biotech AB have planned to initiate a phase III program for the drug.
ACCESSION #
25688191

 

Related Articles

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics